Gastric Adenocarcinoma

News alerts, weekly reports and conference planners

Related cancers:

‹

Gastric Cancer (780)

Gastroesophageal Junction Adenocarcinoma (185)

Gastroesophageal Cancer (41)

Gastric Cancer (780)

Gastroesophageal Junction Adenocarcinoma (185)

Gastroesophageal Cancer (41)

›

No biomarker	Gastric Adenocarcinoma	No biomarker	Gastric Adenocarcinoma	cisplatin + docetaxel + 5-fluorouracil Sensitive: A1 - Approval cisplatin + docetaxel + 5-fluorouracil Sensitive : A1	cisplatin + docetaxel + 5-fluorouracil Sensitive: A1 - Approval cisplatin + docetaxel + 5-fluorouracil Sensitive : A1
PD-L1 expression	Gastric Adenocarcinoma	PD-L1 expression	Gastric Adenocarcinoma	pembrolizumab Sensitive: A2 - Guideline pembrolizumab Sensitive : A2	pembrolizumab Sensitive: A2 - Guideline pembrolizumab Sensitive : A2
HER-2 overexpression	Gastric Adenocarcinoma	HER-2 overexpression	Gastric Adenocarcinoma	trastuzumab Sensitive: A2 - Guideline trastuzumab Sensitive : A2	trastuzumab Sensitive: A2 - Guideline trastuzumab Sensitive : A2
HER-2 overexpression	Gastric Adenocarcinoma	HER-2 overexpression	Gastric Adenocarcinoma	fam-trastuzumab deruxtecan-nxki Sensitive: A2 - Guideline fam-trastuzumab deruxtecan-nxki Sensitive : A2	fam-trastuzumab deruxtecan-nxki Sensitive: A2 - Guideline fam-trastuzumab deruxtecan-nxki Sensitive : A2
PD-L1 expression	Gastric Adenocarcinoma	PD-L1 expression	Gastric Adenocarcinoma	nivolumab Sensitive: A2 - Guideline nivolumab Sensitive : A2	nivolumab Sensitive: A2 - Guideline nivolumab Sensitive : A2
HER-2 overexpression	Gastric Adenocarcinoma	HER-2 overexpression	Gastric Adenocarcinoma	pembrolizumab + trastuzumab Sensitive: A2 - Guideline pembrolizumab + trastuzumab Sensitive : A2	pembrolizumab + trastuzumab Sensitive: A2 - Guideline pembrolizumab + trastuzumab Sensitive : A2
MET expression	Gastric Adenocarcinoma	MET expression	Gastric Adenocarcinoma	AMG 102 Resistant: B - Late Trials AMG 102 Resistant : B	AMG 102 Resistant: B - Late Trials AMG 102 Resistant : B
MET amplification	Gastric Adenocarcinoma	MET amplification	Gastric Adenocarcinoma	AMG 102 Resistant: B - Late Trials AMG 102 Resistant : B	AMG 102 Resistant: B - Late Trials AMG 102 Resistant : B
PD-L1 underexpression	Gastric Adenocarcinoma	PD-L1 underexpression	Gastric Adenocarcinoma	Immunotherapy Resistant: B - Late Trials Immunotherapy Resistant : B	Immunotherapy Resistant: B - Late Trials Immunotherapy Resistant : B
HER-2 negative + PD-L1 expression	Gastric Adenocarcinoma	HER-2 negative + PD-L1 expression	Gastric Adenocarcinoma	pembrolizumab Sensitive: B - Late Trials pembrolizumab Sensitive : B	pembrolizumab Sensitive: B - Late Trials pembrolizumab Sensitive : B
HER-2 underexpression	Gastric Adenocarcinoma	HER-2 underexpression	Gastric Adenocarcinoma	fam-trastuzumab deruxtecan-nxki Sensitive: C1 - Off-label fam-trastuzumab deruxtecan-nxki Sensitive : C1	fam-trastuzumab deruxtecan-nxki Sensitive: C1 - Off-label fam-trastuzumab deruxtecan-nxki Sensitive : C1
HER-2 positive	Gastric Adenocarcinoma	HER-2 positive	Gastric Adenocarcinoma	pembrolizumab + margetuximab-cmkb Sensitive: C2 – Inclusion Criteria pembrolizumab + margetuximab-cmkb Sensitive : C2	pembrolizumab + margetuximab-cmkb Sensitive: C2 – Inclusion Criteria pembrolizumab + margetuximab-cmkb Sensitive : C2
CLDN18.2 expression	Gastric Adenocarcinoma	CLDN18.2 expression	Gastric Adenocarcinoma	zolbetuximab-clzb Sensitive: C2 – Inclusion Criteria zolbetuximab-clzb Sensitive : C2	zolbetuximab-clzb Sensitive: C2 – Inclusion Criteria zolbetuximab-clzb Sensitive : C2
HER-2 amplification	Gastric Adenocarcinoma	HER-2 amplification	Gastric Adenocarcinoma	trastuzumab + avelumab Sensitive: C2 – Inclusion Criteria trastuzumab + avelumab Sensitive : C2	trastuzumab + avelumab Sensitive: C2 – Inclusion Criteria trastuzumab + avelumab Sensitive : C2
PD-L1 expression	Gastric Adenocarcinoma	PD-L1 expression	Gastric Adenocarcinoma	envafolimab Sensitive: C2 – Inclusion Criteria envafolimab Sensitive : C2	envafolimab Sensitive: C2 – Inclusion Criteria envafolimab Sensitive : C2
MET amplification	Gastric Adenocarcinoma	MET amplification	Gastric Adenocarcinoma	crizotinib Sensitive: C3 – Early Trials crizotinib Sensitive : C3	crizotinib Sensitive: C3 – Early Trials crizotinib Sensitive : C3
PD-L1 expression	Gastric Adenocarcinoma	PD-L1 expression	Gastric Adenocarcinoma	pembrolizumab + margetuximab-cmkb Sensitive: C3 – Early Trials pembrolizumab + margetuximab-cmkb Sensitive : C3	pembrolizumab + margetuximab-cmkb Sensitive: C3 – Early Trials pembrolizumab + margetuximab-cmkb Sensitive : C3
ATM mutation	Gastric Adenocarcinoma	ATM mutation	Gastric Adenocarcinoma	Immunotherapy Sensitive: C3 – Early Trials Immunotherapy Sensitive : C3	Immunotherapy Sensitive: C3 – Early Trials Immunotherapy Sensitive : C3
ATR mutation	Gastric Adenocarcinoma	ATR mutation	Gastric Adenocarcinoma	Immunotherapy Sensitive: C3 – Early Trials Immunotherapy Sensitive : C3	Immunotherapy Sensitive: C3 – Early Trials Immunotherapy Sensitive : C3
ATRX mutation	Gastric Adenocarcinoma	ATRX mutation	Gastric Adenocarcinoma	Immunotherapy Sensitive: C3 – Early Trials Immunotherapy Sensitive : C3	Immunotherapy Sensitive: C3 – Early Trials Immunotherapy Sensitive : C3
PD-L1 underexpression	Gastric Adenocarcinoma	PD-L1 underexpression	Gastric Adenocarcinoma	toripalimab-tpzi + surufatinib Sensitive: C3 – Early Trials toripalimab-tpzi + surufatinib Sensitive : C3	toripalimab-tpzi + surufatinib Sensitive: C3 – Early Trials toripalimab-tpzi + surufatinib Sensitive : C3
HER-2 amplification	Gastric Adenocarcinoma	HER-2 amplification	Gastric Adenocarcinoma	HER2 inhibitor Resistant: C3 – Early Trials HER2 inhibitor Resistant : C3	HER2 inhibitor Resistant: C3 – Early Trials HER2 inhibitor Resistant : C3
Chr amplification(11)(q13)	Gastric Adenocarcinoma	Chr amplification(11)(q13)	Gastric Adenocarcinoma	Immunotherapy Resistant: C3 – Early Trials Immunotherapy Resistant : C3	Immunotherapy Resistant: C3 – Early Trials Immunotherapy Resistant : C3
MDM2 amplification	Gastric Adenocarcinoma	MDM2 amplification	Gastric Adenocarcinoma	Immunotherapy Resistant: C3 – Early Trials Immunotherapy Resistant : C3	Immunotherapy Resistant: C3 – Early Trials Immunotherapy Resistant : C3
MDM4 amplification	Gastric Adenocarcinoma	MDM4 amplification	Gastric Adenocarcinoma	Immunotherapy Resistant: C3 – Early Trials Immunotherapy Resistant : C3	Immunotherapy Resistant: C3 – Early Trials Immunotherapy Resistant : C3
CDKN2A deletion	Gastric Adenocarcinoma	CDKN2A deletion	Gastric Adenocarcinoma	Immunotherapy Resistant: C3 – Early Trials Immunotherapy Resistant : C3	Immunotherapy Resistant: C3 – Early Trials Immunotherapy Resistant : C3
CDKN2B deletion	Gastric Adenocarcinoma	CDKN2B deletion	Gastric Adenocarcinoma	Immunotherapy Resistant: C3 – Early Trials Immunotherapy Resistant : C3	Immunotherapy Resistant: C3 – Early Trials Immunotherapy Resistant : C3
PD-L1 expression	Gastric Adenocarcinoma	PD-L1 expression	Gastric Adenocarcinoma	PD-L1 inhibitor Sensitive: C3 – Early Trials PD-L1 inhibitor Sensitive : C3	PD-L1 inhibitor Sensitive: C3 – Early Trials PD-L1 inhibitor Sensitive : C3
MSI-H/dMMR	Gastric Adenocarcinoma	MSI-H/dMMR	Gastric Adenocarcinoma	atezolizumab Sensitive: C3 – Early Trials atezolizumab Sensitive : C3	atezolizumab Sensitive: C3 – Early Trials atezolizumab Sensitive : C3
HER-2 negative	Gastric Adenocarcinoma	HER-2 negative	Gastric Adenocarcinoma	cisplatin + paclitaxel + capecitabine Sensitive: C3 – Early Trials cisplatin + paclitaxel + capecitabine Sensitive : C3	cisplatin + paclitaxel + capecitabine Sensitive: C3 – Early Trials cisplatin + paclitaxel + capecitabine Sensitive : C3
CPEB1 underexpression	Gastric Adenocarcinoma	CPEB1 underexpression	Gastric Adenocarcinoma	5-fluorouracil Sensitive: C3 – Early Trials 5-fluorouracil Sensitive : C3	5-fluorouracil Sensitive: C3 – Early Trials 5-fluorouracil Sensitive : C3
HER-2 negative	Gastric Adenocarcinoma	HER-2 negative	Gastric Adenocarcinoma	envafolimab Sensitive: C3 – Early Trials envafolimab Sensitive : C3	envafolimab Sensitive: C3 – Early Trials envafolimab Sensitive : C3

Gastric Adenocarcinoma

Associations(40)

Associations
(40)